Albany, NY, March 05, 2018 -- In accordance with the market research report by TMR, the world diabetes drugs market stood at a market valuation of around US$ 43.1 bn in the year 2016 and the said market is likely to be valued at around US$ 58.4 bn by the end of the year 2025, rising at a growth rate of 3.6% CAGR over the period of forecast that extends from the year 2017 to 2025.
Illness due to Various Lifestyle Factors to Encourage Market Growth
The growth promoting factors such as increasing per capita income in different parts of the world resulted in adoption of fast food and unhealthy food habits coupled with changing lifestyles have been one of the major factors that resulted in the high prevalence of obesity, which has been as a major cause for diabetes worldwide. Sedentary lifestyle has also resulted in the rise of prevalence of diabetes and as such accelerated the demand for diabetes drugs. The growing prevalence of diabetes in both the developed and developing countries is driving the world market for diabetes drugs. Expanding base of geriatric population worldwide and augmented adoption of therapeutics for type 1 and type 2 diabetes are foreseen to boost the world diabetes drugs market. Research and development activities pertaining to the introduction of better drugs are also accelerating the growth of the said market.
Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14672
North America to Lead the Market with Advanced Treatment Facilities
The world market for diabetes drugs is segmented into major geographies of North America, Latin America, Europe, Asia Pacific, and the North east and Africa. The region of North America accounted for the most of the market revenue in the year 2016, owing to high prevalence of diabetes in the said region. The region of Europe is projected to account for the second large share of the market in the year 2016 due to increased investment in research & development activities and a very promising pipeline of various diabetes drugs in the said region. Asia Pacific is too foreseen to expand fast, owing to the better promotion and awareness promotion in the said region. Furthermore, the region of Middle East & Africa is expected to rise over the period of forecast owing to augmented prevalence of diabetes. In addition to that, rising disposable income particularly in the region of Middle Eastern countries are further expected to boost the market. The region of Latin America is foreseen to progress over the period of forecast due to over-dependence on insulin both by the patients and physicians.
Download PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14672
Transparency Market Research (TMR), in one of its newest market research reports mentions that the international diabetes drugs market to be highly fragmented and fiercely competitive owing to the presence of numerous prominent market vendors. With the expansion and diversification of product portfolio by the already existing market players and entry of new market players, the competition in the said market is very likely to intensify in the years to come. Regional expansion through acquisitions and mergers and various strategic alliances is expected to continue so as to remain another major growth promoting strategy for the participants of the said market.
Request For Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=14672
The report profiles names like Novo Nordisk A/S, Bayer AG, Boehringer Ingelheim GmbH, Merck & Co., Novartis AG, and Sanofi as prominent market players in the international market for diabetes drugs. Apart from these companies, some of the other prominent market players pertaining to the said market are Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Johnson & Johnson, Eli Lilly and Company and so on.
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Contact
Mr. Nachiket Ghumare
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Research Blog: http://theglobalhealthnews.com/


Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
OpenAI Restricts Astra AI Over Cyberattack Risks
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
DeepSeek to Raise AI API Prices as Demand for New Models Surges
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 



